Clinical Case Scenario
A 72-year-old male with severe HFrEF (LVEF 25%) is admitted to the ICU with acute decompensated heart failure - pulmonary oedema with elevated JVP and marked peripheral congestion. His BP is 98/56 mmHg, lactate 1.8 mmol/L, warm extremities and no evidence of cardiogenic shock. He is started on Non-Invasive Ventilatory support.
He receives intravenous furosemide, with brisk diuresis, substantial natriuresis and rapid symptomatic improvement during the first 48 hours.
By day 4, however, he remains clinically congested. Despite progressively increasing the intravenous furosemide dose, urine output and urinary sodium excretion decrease markedly compared with the initial response. His BP remains stable, renal function has not significantly deteriorated, cardiac output is unchanged, and renal ultrasound shows no obstruction.
Right Answer: ✅ A. Hypertrophy of the distal convoluted tubule with increased activity of the Na⁺-Cl⁻ cotransporter. Discussion The diuretic braking phenomenon is an important adaptive mechanism underlying diuretic resistance, particularly during repeated or prolonged loop-diuretic therapy. Loop diuretics such as furosemide inhibit the Na⁺–K⁺–2Cl⁻ cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This produces a marked increase in Na⁺ and fluid delivery to the downstream nephron. With continued therapy, however, the distal nephron progressively adapts to this increased sodium load. The distal convoluted tubule undergoes hypertrophy and functional remodelling, with increased capacity for sodium reabsorption, particularly through the Na⁺–Cl⁻ cotransporter (NCC). Further downstream, enhanced ENaC-mediated Na⁺ reabsorption in the connecting tubule and collecting duct can also contribute. Overall sequence: Loop diuretic → ↓ NKCC2-mediated Na⁺ reabsorption → ↑ distal Na⁺ delivery → distal nephron hypertrophy/remodelling → ↑ NCC/ENaC activity → ↑ distal Na⁺ reabsorption → ↓ net natriuresis Thus, the same dose of loop diuretic produces progressively less sodium excretion over time is the essence of the diuretic braking phenomenon. Important distinction: Diuretic braking ≠ CPDSR • Diuretic braking: a chronic adaptive reduction in natriuretic response during continued loop-diuretic exposure, largely due to distal nephron remodelling and increased sodium reabsorption. • CPDSR (compensatory post-diuretic sodium retention): rebound sodium retention after the diuretic effect wears off, driven partly by neurohormonal activation and restoration of sodium balance. This physiology also provides the rationale for sequential nephron blockade, such as combining a loop diuretic with a thiazide/thiazide-like agent to inhibit NCC-mediated distal sodium reabsorption.
Wrong Answer: ❌ B. Furosemide already inhibits NKCC2. Further downregulation of NKCC2 would tend to reduce sodium reabsorption in the loop and increase natriuresis, rather than explain declining diuretic effectiveness. Braking is predominantly a downstream compensatory response, not loss of the loop target.
Wrong Answer: ❌ C. Reduced proximal tubular NHE3 activity would decrease proximal sodium reabsorption and deliver more sodium to the loop of Henle, which should generally facilitate sodium excretion rather than cause resistance. Chronic loop exposure is not characterized by proximal tubular atrophy as the principal mechanism of braking.
Wrong Answer: ❌ D. ENaC is located predominantly in the late distal nephron - connecting tubule and collecting duct and not the proximal convoluted tubule.
